Molecular Partners AG announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology Annual Meeting 2024, held in Chicago, IL,.
Experts weigh current, future options for AMD management healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin.